Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Genome-based Drug Discovery

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1745038

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1745038

CRISPR Genomic Cure

PUBLISHED:
PAGES: 282 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global CRISPR Genomic Cure Market to Reach US$12.0 Billion by 2030

The global market for CRISPR Genomic Cure estimated at US$3.7 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 21.5% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 23.3% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Libraries segment is estimated at 22.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 28.3% CAGR

The CRISPR Genomic Cure market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 28.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 19.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.2% CAGR.

Global CRISPR Genomic Cure Market - Key Trends & Drivers Summarized

Why Is CRISPR Emerging as a Groundbreaking Platform for Curative Genomic Medicine?

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is revolutionizing the field of medicine by offering a powerful and precise tool for editing genes and potentially curing previously untreatable genetic disorders. Unlike traditional therapies that manage symptoms, CRISPR-based genomic cures target the root cause of disease at the DNA level, making them fundamentally transformative. At its core, CRISPR allows scientists to “cut and paste” sections of DNA with unprecedented accuracy, enabling the correction of mutations responsible for a wide range of conditions-from monogenic diseases like sickle cell anemia and cystic fibrosis to more complex disorders including cancer and certain neurodegenerative diseases. The therapeutic potential of CRISPR has sparked a wave of innovation and investment across biotech and pharmaceutical sectors, with several therapies entering clinical trials and some showing promising early results. The simplicity, cost-effectiveness, and versatility of CRISPR compared to earlier gene-editing methods such as TALENs or zinc finger nucleases have accelerated its adoption in both research and clinical settings. Additionally, advancements like CRISPR-Cas9, base editing, and prime editing are further expanding its therapeutic possibilities. As the medical community shifts its focus toward precision medicine and curative treatments, CRISPR stands at the forefront holding promise for eradicating inherited diseases and transforming the future of healthcare.

How Are Clinical Trials, Regulatory Evolution, and Biotech Innovation Driving CRISPR Therapies Forward?

The global advancement of CRISPR-based genomic cures is being propelled by a growing number of clinical trials, progressive regulatory frameworks, and robust innovation within the biotechnology industry. Clinical trials are currently underway for a variety of applications, including blood disorders such as beta-thalassemia and sickle cell disease, where initial results have shown significant improvements in patient outcomes following a single treatment. Regulatory bodies like the U.S. FDA and the European Medicines Agency are adapting their evaluation criteria to accommodate the complexities of gene-editing therapies, issuing specific guidelines for genome-modifying technologies and expediting the approval process through designations like Orphan Drug, Fast Track, and Breakthrough Therapy. This regulatory openness is fostering a more favorable environment for companies to bring CRISPR treatments to market. Meanwhile, biotech startups and pharmaceutical giants are forming partnerships to combine scientific expertise, intellectual property, and clinical infrastructure to accelerate development. The creation of delivery systems-such as viral vectors and lipid nanoparticles-that ensure precise and safe transport of CRISPR components to target cells is a major area of innovation. Moreover, developments in off-target effect detection and mitigation are increasing the safety profile of CRISPR therapies. With a growing ecosystem of investors, researchers, and regulators working collaboratively, the clinical and commercial pathway for CRISPR genomic cures is becoming clearer and more achievable.

What Ethical, Social, and Technical Considerations Are Shaping the Global CRISPR Landscape?

As CRISPR moves closer to clinical mainstream adoption, ethical, social, and technical considerations are becoming increasingly critical to the technology’s responsible development and deployment. One of the most prominent ethical concerns revolves around germline editing-changes to embryos or reproductive cells that can be passed on to future generations. While current therapeutic applications are largely confined to somatic cell editing (non-inheritable), public discourse and regulatory policies continue to wrestle with the implications of permanent genomic alterations. Questions of equity and access also dominate discussions: Will CRISPR therapies be affordable and available to all, or only to wealthy patients in developed countries? These concerns are driving calls for global governance frameworks and bioethics oversight that ensure transparency, accountability, and inclusivity. Technically, issues such as off-target effects, incomplete edits, immune responses, and long-term safety remain focal points of ongoing research. Scientists are also working on refining CRISPR systems to reduce unintended genetic changes and improve targeting specificity. At the societal level, patient advocacy groups, public awareness campaigns, and stakeholder engagement initiatives are playing a vital role in shaping perceptions and policies. Additionally, cultural and religious attitudes toward genetic modification vary widely, adding complexity to global adoption. These intertwined challenges underscore the need for interdisciplinary collaboration among scientists, ethicists, policymakers, and communities to harness CRISPR’s full potential in an ethical and equitable manner.

What Are the Key Drivers Fueling the Growth of the CRISPR Genomic Cure Market Worldwide?

The growth in the CRISPR genomic cure market is driven by a confluence of scientific breakthroughs, increasing prevalence of genetic disorders, supportive regulatory environments, and rising investments from public and private sectors. A major driver is the rising global burden of genetic diseases-both rare and common-which remain poorly managed or incurable through conventional therapies. CRISPR’s ability to offer a one-time, potentially permanent solution to these conditions is a major draw for healthcare systems aiming to reduce long-term treatment costs and improve patient outcomes. The sharp increase in genomics research funding and CRISPR-related patents has led to a surge in pipeline development across biotech firms, academic institutions, and contract research organizations. Additionally, growing public and institutional acceptance of gene-editing as a valid therapeutic approach is encouraging more clinical trials and cross-border collaborations. Technological improvements in guide RNA design, delivery vectors, and gene-editing enzymes are lowering development barriers and enhancing therapeutic efficacy. Meanwhile, the integration of CRISPR with AI, big data analytics, and personalized medicine platforms is enabling more accurate patient stratification and treatment planning. Health policy initiatives aimed at supporting rare disease research, combined with patient advocacy, are further pushing CRISPR into regulatory fast lanes. Together, these drivers are catalyzing a paradigm shift in the life sciences sector, where curative genomic therapies are not only a scientific aspiration but an imminent reality poised to redefine the future of medicine.

SCOPE OF STUDY:

The report analyzes the CRISPR Genomic Cure market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Kits & Reagents, Libraries, Vector Design, Assay Design, Other Product Types); Application (Oncology, Genetic Diseases, Genomic Engineering, Other Applications); End-User (Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Beam Therapeutics
  • Caribou Biosciences
  • CRISPR Biotech Engineering
  • CRISPR Therapeutics
  • Editas Medicine
  • ERS Genomics
  • GenScript
  • Horizon Discovery
  • Inscripta
  • Intellia Therapeutics
  • Mammoth Biosciences
  • Prime Medicine
  • Scribe Therapeutics
  • Synthego
  • Takara Bio
  • Thermo Fisher Scientific
  • ToolGen
  • Vertex Pharmaceuticals
  • Verve Therapeutics
  • Wave Life Sciences

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34864

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • CRISPR Genomic Cure - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthroughs in Gene Editing Technology Throw the Spotlight on CRISPR as a Curative Therapeutic Platform
    • Surging Investment in Genomic Medicine Drives Development of CRISPR-Based One-Time Treatments
    • Expansion of Rare and Monogenic Disease Pipelines Strengthens the Business Case for CRISPR Therapeutics
    • Push Toward Precision Medicine Accelerates the Use of CRISPR in Targeted and Cell-Specific Gene Correction
    • Growing Demand for Durable and Permanent Cures Fuels Interest in CRISPR Over Conventional Chronic Therapies
    • CRISPR-Cas Variants and Next-Gen Editing Systems Generate Opportunities for Enhanced Specificity and Safety
    • Rise in Ex Vivo Cell Therapy Applications Sustains Momentum for CRISPR in Oncology and Hematologic Disorders
    • Ethical Debates and Governance Frameworks Drive Global Dialogue on Germline and Heritable Gene Editing
    • CRISPR Delivery Innovations Throw the Spotlight on Lipid Nanoparticles, AAV, and Electroporation Methods
    • Integration with AI-Powered Genomics and Bioinformatics Enhances Target Identification and Editing Efficiency
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CRISPR Genomic Cure Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for CRISPR Genomic Cure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Libraries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Libraries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vector Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Vector Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Assay Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Assay Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Genetic Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Genetic Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Genetic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Genetic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Genomic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Genomic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • JAPAN
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • CHINA
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • EUROPE
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for CRISPR Genomic Cure by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • FRANCE
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • GERMANY
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 88: Spain Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Spain 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 90: Spain Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Spain 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 94: Russia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Russia 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 96: Russia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Russia 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 106: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • AUSTRALIA
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 112: Australia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Australia 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 114: Australia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Australia 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • INDIA
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 118: India Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: India 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 120: India Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: India 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 124: South Korea Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: South Korea 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 126: South Korea Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: South Korea 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 130: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 132: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • LATIN AMERICA
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for CRISPR Genomic Cure by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 138: Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Latin America 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 142: Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Latin America 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 144: Argentina Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Argentina 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 148: Argentina Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Argentina 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 150: Brazil Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Brazil 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 154: Brazil Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Brazil 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • MEXICO
    • TABLE 156: Mexico Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Mexico 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 160: Mexico Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Mexico 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 162: Rest of Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 163: Rest of Latin America 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 166: Rest of Latin America Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Rest of Latin America 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • MIDDLE EAST
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for CRISPR Genomic Cure by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 172: Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Middle East 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 174: Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Middle East 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 178: Iran Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Iran 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 180: Iran Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Iran 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 184: Israel Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Israel 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 186: Israel Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Israel 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 190: Saudi Arabia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: Saudi Arabia 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 192: Saudi Arabia Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: Saudi Arabia 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 196: UAE Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: UAE 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 198: UAE Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: UAE 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 202: Rest of Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Rest of Middle East 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 204: Rest of Middle East Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Rest of Middle East 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030
  • AFRICA
    • CRISPR Genomic Cure Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Product Type - Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa 6-Year Perspective for CRISPR Genomic Cure by Product Type - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Vector Design, Assay Design and Other Product Types for the Years 2025 & 2030
    • TABLE 208: Africa Recent Past, Current & Future Analysis for CRISPR Genomic Cure by End-user - Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 209: Africa 6-Year Perspective for CRISPR Genomic Cure by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations, Genetic Research Laboratories and Other End-Users for the Years 2025 & 2030
    • TABLE 210: Africa Recent Past, Current & Future Analysis for CRISPR Genomic Cure by Application - Oncology, Genetic Diseases, Genomic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 211: Africa 6-Year Perspective for CRISPR Genomic Cure by Application - Percentage Breakdown of Value Sales for Oncology, Genetic Diseases, Genomic Engineering and Other Applications for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!